- Home
- CRDF
as 11-13-2025 3:45pm EST
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 152.3M | IPO Year: | N/A |
| Target Price: | $10.63 | AVG Volume (30 days): | 723.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $5.64 | Next Earning Date: | 11-06-2025 |
| Revenue: | $501,000 | Revenue Growth: | -27.18% |
| Revenue Growth (this year): | -35.04% | Revenue Growth (next year): | -24.43% |
Latest Cardiff Oncology Inc. News
CRDF Breaking Stock News: Dive into CRDF Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
Associated Press Finance
8 days ago
Cardiff Oncology: Q3 Earnings Snapshot
GlobeNewswire
8 days ago
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
GlobeNewswire
10 days ago
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
MT Newswires
5 months ago
Jefferies Initiates Cardiff Oncology at Hold With $3.50 Price Target
TipRanks
5 months ago
Cardiff Oncology to share CRDF-004 trial data on July 29
TipRanks
5 months ago
Cardiff selloff brings attractive entry point, says H.C. Wainwright
GlobeNewswire
5 months ago
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Compare CRDF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDF Cardiff Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.